Skip to main content
SpringerLink
Log in

Prevalence of primaryHelicobacter pylori resistance to metronidazole and clarithromycin in The Netherlands

  • Notes
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

Abstract

The minimum inhibitory concentrations of metronidazole and clarithromycin were determined for 780Helicobacter pylori strains collected in 1994 and 1995 from three different regions in The Netherlands. The overall prevalence of primary metronidazole resistance was 17%, with resistance found more frequently in women (24%) than in men (13%). There was no significant difference between the levels of resistance in the three regions. Primary clarithromycin resistance was rare (1%) and relatively infrequent as compared to that found in other countries. Four of the six strains resistant to clarithromycin were also resistant to metronidazole.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Thijs JC, Kuipers EJ, van Zwet AA, Peña AS, de Graaff J: Treatment ofHelicobacter pylori infections. A review of the current indications. Quarterly Journal of Medicine 1995, 88: 369–389.

    Google Scholar 

  2. Bazzoli F, Zagari RM, Fossi S, Pozzato P, Alampi G, Simoni P: Short-term low-dose triple therapy for the eradication ofHelicobacter pylori. European Journal of Gastroenterology and Hepatology 1994, 6: 773–777.

    Google Scholar 

  3. de Boer WA, Driessen WMM, Potters VPJ, Tytgat GNJ: Randomized study comparing 1 with 2 weeks of quadruple therapy for eradicatingHelicobacter pylori. American Journal of Gastroenterology 1994, 89: 1993–1997.

    PubMed  Google Scholar 

  4. de Boer WA, Tytgat GNJ: The best therapy forHelicobacter pylori infection: should efficacy or side-effect profile determine our choice? Scandinavian Journal of Gastroenterology 1995, 30: 401–407.

    PubMed  Google Scholar 

  5. Burette A, Glupczynski Y, De Prez C: Evaluation of various multidrug eradication regimens forHelicobacter pylori. European Journal of Gastroenterology and Hepatology 1992, 4: 817–823.

    Google Scholar 

  6. Burette A, Glupczynski Y:Helicobacter pylori: the place of the new macrolides in the eradication of bacteria in peptic ulcer disease. Infection 1995, 23, Supplement 1: 44–52.

    Google Scholar 

  7. Cayla R, Zerbib F, Talbi P, Megraud F, Lamouliatte H: Pre-and post-treatment clarithromycin resistance ofHelicobacter pylori strains: a key factor of treatment failure. Gut 1995, 37, Supplement 1: A55, abstract 217.

    Google Scholar 

  8. European Study Group on Antibiotic Susceptibility ofH. pylori. Results of a multicentre European survey in 1991 of metronidazole resistance inHelicobacter pylori. European Journal of Clinical Microbiology & Infectious Diseases 1992, 11: 777–781.

    Google Scholar 

  9. Goodwin CS, Marshall BJ, Blincow ED, Wison DH, Blackbourn S, Phillips M: Prevention of nitroimidazole resistance inCampylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies. Journal of Clinical Pathology 1988, 41: 207–210.

    PubMed  Google Scholar 

  10. Parasakthi N, Goh KL: Primary and acquired resistance to clarithromycin amongHelicobacter pylori strains in Malaysia. American Journal of Gastroenterology 1995, 90: 519.

    Google Scholar 

  11. van Zwet AA, Thijs JC, Oom JAJ, Hoogeveen J, Düringshoff BL: Failure to eradicateHelicobacter pylori in patients with metronidazole resistant strains. European Journal of Gastroenterology and Hepatology 1993, 5: 185–186.

    Google Scholar 

  12. Xia HX, Buckley M, Hyde D, Keane CT, O'Morain CA: Effects of antibiotic resistance on clarithromycin-combined triple therapy forHelicobacter pylori. Gut 1995, 37, Supplement 1: A55, abstract 218.

    Google Scholar 

  13. Glupczynski Y: In vitro susceptibility testing ofHelicobacter pylori to antimicrobial agents: basis for treatment or microbiologists' obsession? Zeitblatt für Bakteriologie 1993, 280: 227–238.

    Google Scholar 

  14. Malanoski GJ, Eliopoulos GM, Ferraro MJ, Moellering JR: Effect of pH variation on the susceptibility ofHelicobacter pylori to three macrolide antimicrobial agents and temafloxacin. European Journal of Clinical Microbiology & Infectious Diseases 1993, 12: 131–133.

    Google Scholar 

  15. Peterson W: Clarithromycin as monotherapy for eradication ofHelicobacter pylori. American Journal of Gastroenterology 1992, 87: 1274.

    Google Scholar 

  16. Logan RP, Gummett PA, Schaufelberger HD, Greaves RR, Mendelson GM, Thomas PH, Baron JH, Misiewicz JJ: Eradication ofHelicobacter pylori with clarithromycin and omeprazole. Gut 1994, 35: 323–326.

    PubMed  Google Scholar 

  17. Al-Assi MT, Ramirez FC, Lew GM, Genta RM, Graham DY: Clarithromycin, tetracycline, and bismuth: a new non-metronidazole therapy forHelicobacter pylori infection. American Journal of Gastroenterology 1994, 89: 1203–1205.

    PubMed  Google Scholar 

  18. Thijs JC, van Zwet AA, Moolenaar W, Oom JAJ, de Korte H, Runhaar EA: Ciarithromycin, an alternative to metronidazole in the triple therapy ofHelicobacter pylori infection. Alimentary Pharmacology and Therapeutics 1994, 8: 131–134.

    PubMed  Google Scholar 

  19. Rautelin H, Seppälla K, Renkonen OV, Vaino U, Kosunen TU: Role of metronidazole resistance in therapy ofHelicobacter pylori infections. Antimicrobial Agents and Chemotherapy 1992, 36: 163–166.

    PubMed  Google Scholar 

  20. Cederbrant G, Kahlmeter G, Ljungh A: The E-test for antimicrobial susceptibility testing ofHelicobacter pylori. Journal of Antimicrobial Chemotherapy 1993, 31: 65–71.

    Google Scholar 

  21. Glupczynski Y, Labbé M, Hansen W, Crokaert F, Yourassowsky E: Evaluation of the E-test for quantitative antimicrobial susceptibility testing ofHelicobacter pylori. Journal of Clinical Microbiology 1991, 29: 2072–2075.

    PubMed  Google Scholar 

  22. Cayla R, Lamouiliatte H, Megraud F, Quinton A: Primary resistance ofHelicobacter pylori strains to metronidazole and to clarithromycin in France in 1993. Gastroenterology 1994, 106: A61.

    Google Scholar 

  23. Xia HX, Keane CT, O'Morain CA: Prevalence and stability of clarithromycin resistance inHelicobacter pylori: clinical implications. American Journal of Gastroenterology 1994, 89: 1391.

    Google Scholar 

  24. Hachem CY, Clarridge JE, Evans DG, Cox S, Flamm R, Graham DY: Analysis of pretreatment in vitro microbiology to evaluate eradication ofH. pylori in patients with duodenal ulcers. American Journal of Gastroenterology 1994, 89: 1373.

    Google Scholar 

  25. Becx MCJM, Janssen AJHM, Clasener HAL, de Koning RW: Metronidazole-resistantHelicobacter pylori. Lancet 1990, i: 976–977.

    Google Scholar 

  26. van Zwet AA, Thijs JC, Schievink-de Vries W, Schiphuis J, Snijder JAM: In vitro studies on the stability and development of metronidazole resistance inHelicobacter pylori. Antimicrobial Agents and Chemotherapy 1994, 38: 360–362.

    PubMed  Google Scholar 

  27. Versalovic J, Shortridge D, Kibler K, Griffy MV, Beyer J, Flamm RK, Tanaka SK, Graham DY, Go MF: Mutations in 23S rRNA are associated with clarithromycin resistance inHelicobacter pylori. Antimicrobial Agents and Chemotherapy 1996, 40: 477–480.

    PubMed  Google Scholar 

  28. Graham DY: A reliable cure ofHelicobacter pylori infection? Gut 1995, 37: 154–156.

    PubMed  Google Scholar 

  29. van Zwet AA, Thijs JC, Roosendaal R, Kuipers EJ, Peña S, de Graaff J: Practical diagnosis ofHelicobacter pylori infection. European Journal of Gastroenterology and Hepatology 1996, 8: 501–506.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Regional Public Health Laboratory Groningen/Drenthe, Bethesda Hospital, Dr. G.H. Amshoffweg 1, 7909, AA Hoogeveen, The Netherlands

    A. A. van Zwet

  2. Department of Internal Medicine, Sint Anna Ziekenhuis, Johannes Zwijssenlaan 121, 5340, BE Oss, The Netherlands

    W. A. de Boer

  3. Laboratory for Medical Microbiology, Bosch Medicentrum, Nieuwstraat 34, 5211, NL Den Bosch, The Netherlands

    P. M. Schneeberger

  4. Department of Medical Microbiology, Academic Medical Centre, Meibergdreef 9, 1105, AZ Amsterdam, The Netherlands

    J. Weel

  5. Laboratory for Medical Microbiology PAMM, Postbus 2, 5500, AA Veldhoven, The Netherlands

    A. R. Jansz

  6. Department of Internal Medicine, Bethesda Hospital, Dr. G.H. Amshoffweg 1, 7909, AA Hoogeveen, The Netherlands

    J. C. Thijs

Authors
  1. A. A. van Zwet
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. A. de Boer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. M. Schneeberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Weel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. R. Jansz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. C. Thijs
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

van Zwet, A.A., de Boer, W.A., Schneeberger, P.M. et al. Prevalence of primaryHelicobacter pylori resistance to metronidazole and clarithromycin in The Netherlands. Eur. J. Clin. Microbiol. Infect. Dis. 15, 861–864 (1996). https://doi.org/10.1007/BF01691216

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01691216

Keywords

Search

Navigation